Management of Drug-Induced Interstitial Lung Disease

home / insights / management-of-drug-induced-interstitial-lung-disease
Antibody Drug Conjugates and Interstitial Lung Disease Risk

EP. 1: Antibody Drug Conjugates and Interstitial Lung Disease Risk

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Risks for Developing ILD and Personal Experience

EP. 2: Risks for Developing ILD and Personal Experience

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Changes in Cancer Treatment and Management of ILD

EP. 3: Changes in Cancer Treatment and Management of ILD

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Use of Antibody Drug Conjugates and Potential for ILD

EP. 4: Use of Antibody Drug Conjugates and Potential for ILD

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Rate and Class Effect of ILD with Antibody Drug Conjugates

EP. 5: Rate and Class Effect of ILD with Antibody Drug Conjugates

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
CDK 4/6 Inhibitors and Identifying ILD in Patients

EP. 6: CDK 4/6 Inhibitors and Identifying ILD in Patients

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Managing Patient Symptoms and Clinician Education

EP. 7: Managing Patient Symptoms and Clinician Education

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials

EP. 8: Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Patient Factors for Developing ILD and Personal Experience

EP. 9: Patient Factors for Developing ILD and Personal Experience

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Patient Management upon Developing ILD and Education

EP. 10: Patient Management upon Developing ILD and Education

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Potential Risk of Drug-Induced Interstitial Lung Disease

EP. 11: Potential Risk of Drug-Induced Interstitial Lung Disease

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Personal Experience with Drug-Induced ILD

EP. 12: Personal Experience with Drug-Induced ILD

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Rate of ILD and Monitoring Parameters

EP. 13: Rate of ILD and Monitoring Parameters

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Identifying Drug-Induced ILD

EP. 14: Identifying Drug-Induced ILD

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Patient Management and Educational Tools for ILD

EP. 15: Patient Management and Educational Tools for ILD

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Role of Antibody Drug Conjugates and Personal Experience

EP. 16: Role of Antibody Drug Conjugates and Personal Experience

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Risks for Developing ILD in Gastrointestinal Cancer Studies

EP. 17: Risks for Developing ILD in Gastrointestinal Cancer Studies

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Risk of ILD as a Class Effect and Identifying ILD

EP. 18: Risk of ILD as a Class Effect and Identifying ILD

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Changes in Treatment Goals due to Drug Induced ILD

EP. 19: Changes in Treatment Goals due to Drug Induced ILD

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Management of Patients Who Develop ILD

EP. 20: Management of Patients Who Develop ILD

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020
Educational Tools for Possible Drug-Induced ILD

EP. 21: Educational Tools for Possible Drug-Induced ILD

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020